Lin Gui Shaoyan Liu Ye Zhang Yuankai Shi
10.2147/OTT.S305196
Onco Targets Ther
2021 Apr 20;14:2741-2746.
nras mutation pd-1 inhibitor tert promoter mutations tp53 mutations anaplastic thyroid carcinoma anti-angiogenesis drug next-generation sequencing
CC BY-NC
https://pubmed.ncbi.nlm.nih.gov/33907417/
Case Reports
PMC8068508
33907417
A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report
2021